BSI News 3.89 Alon Holdings - Blue Square Israel Ltd (BSI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alon Holdings - Blue Square Israel Ltd (BSI) 3.89 $BSI

Alon Blue Square Israel Ltd. Announces Agreement for Private Placement in Israel of Additional Series C Notes
PR Newswire - Thu Apr 03, 12:41PM CDT
Alon Blue Square Israel Ltd. ("Alon Blue Square" or the "Company" announced today that it had agreed with Israeli institutional investors to issue to such investors in a private placement NIS 150 million par value (approximately $43.2 million) of additional Series C Notes (the "Additional Series C Notes" in consideration for an aggregate sum of approximately NIS 151 million (approximately $43.5 million) (the "Private Placement" .

Alon Blue Square Israel Ltd. (NYSE:BSI) Announces The Financial Results For The First Nine Months And The Third Quarter Of 2013[1]
PR Newswire - Wed Nov 27, 10:41AM CST
-- A second quarter of improvement in EBITDA in the Supermarket segment - the EBITDA in the segment amounted to NIS 63 million (3.9%) compared to NIS 51 million (3.2%) in the previous quarter and NIS 37 million (2.3%) in the first quarter of the year.

Alon Blue Square Israel Ltd. (NYSE: BSI) Announces The Financial Results For The First Half And The Second Quarter Of 2013[1]
PR Newswire - Thu Aug 29, 6:15AM CDT
-- Increase of 116% in cash flows from operating activity in the first half of 2013 and an increase of 165% in this quarter, compared to the corresponding periods, to NIS 503 million in the first half and NIS 194 million in the quarter.

XLNX, ALTR, DSCO, EXPO, XRTX, BSI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jul 18, 5:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of XILINX, INC. (NASDAQ:XLNX), Altera Corp (NASDAQ:ALTR), Discovery Laboratories Inc (NASDAQ SCO), Exponent Inc (NASDAQ:EXPO), Xyratex Ltd (NASDAQ:XRTX), Alon Holding Blue Square Israel Ltd (NYSE:BSI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

Alon Blue Square Israel privately places approximately USD27.3m of additional Series C notes in Israel
M2 - Thu Jun 27, 6:53AM CDT
Alon Blue Square Israel Ltd (NYSE:BSI), an Israeli retail, company, announced on Wednesday that it has agreed with Israeli institutional investors to issue to such investors, in a private placement, approximately USD27.52m par value of additional Series C notes in consideration for an aggregate sum of approximately USD27.33m.

Alon Blue Square Israel Ltd. Announces a Private Placement in Israel of Additional Series C Notes
PR Newswire - Wed Jun 26, 7:41AM CDT
Alon Blue Square Israel Ltd. (NYSE: BSI) (hereinafter: "Alon Blue Square" or the "Company" announced today that it has agreed with Israeli institutional investors to issue to such investors in a private placement NIS 100 million par value (approximately $27.52 million) of additional Series C Notes (the "Additional Series C Notes" in consideration for an aggregate sum of approximately NIS 99.3 million (approximately $27.33 million) (the "Private Placement" .

Alon Blue Square - Israel Ltd. (NYSE: BSI) Announces The Financial Results For The First Quarter Of 2013[1]
PR Newswire - Thu May 30, 11:16AM CDT
-- Cash flows from operating activity amounted to NIS 309 million in this quarter, an increase of 93%, the Adjusted EBITDA in this quarter amounted to NIS 98 million compared to NIS 115 million in the corresponding quarter last year.

Alon Blue Square Israel Ltd. Announces Midroog Ltd. Rating of "A2/Negative" for Series A and C Bonds and Reaffirmation of the "P-1" Rating for Commercial Paper
PR Newswire - Mon May 13, 7:02AM CDT
Alon Blue Square Israel Ltd. (NYSE: BSI) (hereinafter: "the Company" announced today that Midroog Ltd., an Israeli rating agency and a 51% subsidiary of Moody's ("Midroog" , announced that it had reaffirmed the "A2" rating of the Series A and C bonds issued by the Company while changing the rating outlook from stable to negative. In addition, Midroog reaffirmed the "P-1" rating for commercial paper issued by the Company in a sum of NIS 75 million up to NIS 120 million.

Alon Holdings Blue Square - Israel Ltd. Announces Name Change to Alon Blue Square Israel Ltd.
PR Newswire - Tue Apr 30, 6:27AM CDT
ï"

Alon Holdings Blue Square Israel Ltd Announces Filing of its Annual Report on Form 20-F
PR Newswire - Mon Apr 29, 1:05PM CDT
Alon Holdings Blue Square-Israel Ltd. (NYSE: BSI) (hereinafter: "Alon Holdings" announced that it filed on April 29, 2013 its Annual Report on Form 20-F for the year ended December 31, 2012. A copy of the Annual Report on Form 20-F is available to be viewed or downloaded on Alon Holdings' website at http://www.bsi.co.il/bsi/en/?page_id=146. In addition, shareholders of Alon Holdings may obtain, free of charge, a printed copy of Alon Holdings' complete audited financial statements, by sending a request to Alon Holdings' CFO, Mr. Dror Moran (email: cfo@bsi.co.il ), or by calling 972-3-9282220.

Alon Holdings Blue Square-Israel Announces Appointment of Limor Ganot as Co-CEO
PR Newswire - Fri Mar 22, 5:57AM CDT
Alon Holdings Blue Square - Israel Ltd. (NYSE: BSI) (hereinafter: "Alon Holdings" announced today that Ms. Limor Ganot has been appointed to serve as the Co-CEO of Alon Holdings, alongside current CEO and Chief Operating Decision Maker Mr. David Wiessman, commencing April 1, 2013.

Alon Holdings Blue Square - Israel Ltd. (NYSE:BSI) Announces the Financial Results for the Fourth Quarter of 2012
PR Newswire - Fri Mar 22, 5:42AM CDT
-- In the Commercial and Fueling sites: A material improvement in the operating profit in this quarter compared to the corresponding quarter last year. The operating profit in this quarter, excluding inventory loss, amounted to NIS 34 million (increase of 100%).

FXA, DXJ, SCHN, OCLR, EPIQ, BSI Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 27, 5:52AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CurrencyShares Australian Dollar Trust (NYSE:FXA), WisdomTree Japan Hedged Equity Fund (NYSE XJ), Schnitzer Steel Industries Inc (NASDAQ:SCHN), Oclaro Inc (NASDAQ:OCLR), Epiq Systems Inc (NASDAQ:EPIQ), Alon Holding Blue Square Israel Ltd (NYSE:BSI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 123

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 233

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 370

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading

Top 5 Most Recently Viewed Articles

VOOG's 15-Year Climb: Compounding Gains or Just a Mirage?

Updated Category News Views 255

Fifteen years back, you could have dropped $1000 into the Vanguard S&P 500 Growth ETF (NYSE:VOOG), and that cash would’ve exploded into a whopping $7,164.65 today. That’s a staggering annualized return of 14.01%, comfortably outpacing the market by about 2.35%. Sounds easy, right? But let’s peel back this seemingly golden curtain. VOOG's Performance: The Big Picture...

Continue Reading
Mercer International Inc. Faces Financial Challenges in Q2 2025

Updated Category News Views 256

Financial Overview of Mercer International Inc. for Q2 2025 Mercer International Inc. recently disclosed its financial performance for the second quarter of 2025, revealing significant challenges. The company reported an Operating EBITDA of negative $20.9 million alongside a net loss of $86.1 million, a stark contrast to the positive $30.4 million Operating EBITDA and a...

Continue Reading
EU's Strategic Response to Potential Trade Challenges with Trump

Updated Category News Views 167

EU's Trade Engagement Strategy with the New Administration The European Union is gearing up for an essential phase in its trade relations with the U.S. as Donald Trump prepares to take office once again. The EU's ministers have clearly expressed the need to foster constructive dialogue regarding trade policies while remaining vigilant about any potential tariff...

Continue Reading
Regenative Labs Casts Spotlight on Plantar Fascia Innovations

Updated Category News Views 44

Rethinking Plantar Fasciitis with Wharton’s Jelly When it comes to those of us keeping an eye on regenerative medicine, it’s like standing on the edge of a wild frontier sometimes. Today, we’ve got Regenative Labs out of Pensacola shining a light on something that’s often a real pain—literally and figuratively: plantar fasciitis. Clinical Studies with Promising...

Continue Reading
GC Biopharma's BARYCELA Secures Marketing Authorization

Updated Category News Views 171

GC Biopharma's Breakthrough with BARYCELA GC Biopharma, a prominent South Korean pharmaceutical company, has achieved a significant milestone with the recent marketing authorization of its varicella vaccine, BARYCELA, in Vietnam. This accomplishment follows earlier domestic approval and WHO Pre-Qualification, demonstrating the company’s commitment to expanding its...

Continue Reading